Efficacy and Safety of Reparixin in Pancreatic Islet Auto-transplantation
Status:
Completed
Trial end date:
2018-01-01
Target enrollment:
Participant gender:
Summary
The study is a phase 2/3, multicenter, double-blind, parallel assignment study. It involves
100 adult recipients of an intra-hepatic pancreatic Islet Auto-Transplantation (IAT).
The objective of this clinical trial is to assess whether reparixin leads to improved
transplant outcome as measured by the proportion of insulin-independent patients following
IAT. The safety of reparixin in the specific clinical setting will be also evaluated.